Voxelotor (Oxbryta)
Small molecule
Also known as GBT440
Evidence outlook · regulatory status
US approval withdrawn: Sickle Cell Disease (FDA, approved 2019-11-25)
The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2026-07-31. Development was discontinued on 2024-09-25, on a safety finding. The trials below are the product's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Idiopathic Pulmonary Fibrosis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Voxelotor (Oxbryta): this drug | Discontinued | Small molecule | Hemoglobin S (HbS) | not yet graded | No reviewed efficacy summary in this indication | |
| Nerandomilast (Jascayd) | Approved | Small molecule | PDE4B | Reliable signal | NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | Partial signal | NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results). NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results). | |
| Pirfenidone (Esbriet) | Approved | Small molecule | Pyridone | Reliable signal | NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results). | |
| Treprostinil (Tyvaso DPI) | Approved(overall) | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-722 | Phase 1(overall) | Small molecule | LPAR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Ziritaxestat | Discontinued | Small molecule | autotaxin (ENPP2) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent